List view / Grid view
17 April 2015 | By Victoria White
Latest data from the ongoing AURA study of AZD9291 demonstrated a median progression free survival of 13.5 months in patients with advanced EGFRm NSCLC...
31 March 2015 | By Victoria White
Syndax and Merck have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining entinostat with Keytruda (pembrolizumab)...
9 December 2014 | By Eli Lilly and Company
On 8th December 2014, the Scottish Medicines Consortium accepted for use within NHS Scotland Alimta (pemetrexed) monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (other than predominantly squamous cell histology) in patients whose disease has not progressed immediately following platinum-based chemotherapy...
16 July 2013 | By Boehringer Ingelheim
First approval for afatinib, the frontrunner from Boehringer Ingelheim’s new oncology pipeline...
15 May 2013 | By Astellas Pharma Inc.
The FDA also approved the cobas® EGFR Mutation Test, which was developed by Roche and validated in the pivotal EURTAC study...
Lonza and Agennix AG announced today an agreement for the production of Agennix’s first-in-class oral Dendritic Cell Mediated Immunotherapy (DCMI), talactoferrin, currently in Phase III testing for the treatment of non-small cell lung cancer (NSCLC).
26 August 2011 | By Abbott
Represents significant advance in personalised medicine for patients with non-small-cell lung cancer...
